Authors/Disclosures
|
John A. Messenheimer, Jr., MD
|
Dr. Messenheimer has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Zynerba Pharmaceuticals. Dr. Messenheimer has received intellectual property interests from a discovery or technology relating to health care. Dr. Messenheimer has received intellectual property interests from a discovery or technology relating to health care. Dr. Messenheimer has received intellectual property interests from a discovery or technology relating to health care. |
|
Bibiana Bielekova, MD, FAAN
(Neuroimmunological Diseases Section/NIAID/NIH)
|
Dr. Bielekova has received research support from National Institutes of Allergy and Infectious Diseases. Dr. Bielekova has received intellectual property interests from a discovery or technology relating to health care. Dr. Bielekova has received publishing royalties from a publication relating to health care. |
|
Susan Kerls
(GlaxoSmithKline)
|
No disclosure on file |
|
|
No disclosure on file |
|
|
No disclosure on file |
|
Paul Caldwell
|
No disclosure on file |
|
Salam Bachour
|
No disclosure on file |
|
Marco A. Tapia Maltos, MD, PhD
|
No disclosure on file |
|
Anne E. Hammer
(Glaxo Welcome)
|
No disclosure on file |
|
Ann Weideman
|
No disclosure on file |
|
Jouko I. Isojarvi, MD, PhD
(Lundbeck)
|
No disclosure on file |
|
Peter Kosa, PhD
(NIH/NINDS)
|
Dr. Kosa has nothing to disclose. |
|
Mika Komori
|
Mika Komori has received personal compensation for serving as an employee of Eli Lilly K.K.. |
|
|
No disclosure on file |
|
|
No disclosure on file |